Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.59 |
| ▸ | HTR2C | P28335 | 2/20 | 0.59 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | MTNR1A | P48039 | 7/20 | 0.50 |
| ▸ | MTNR1B | P49286 | 7/20 | 0.50 |
| ▸ | PARP1 | P09874 | 1/20 | 0.48 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | OPA1 | O60313 | 1/20 | 0.44 |
| ▸ | EIF5B | O60841 | 1/20 | 0.44 |
| ▸ | MET | P08581 | 1/20 | 0.44 |
| ▸ | HMOX2 | P30519 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17553683 | 0.95 | HTR2A (0.54) | HTR2AHTR2CUSP2ALDH1A1HPGD | |
| SCHEMBL23221087 | 0.87 | HPGD (0.55) | HTR2AHTR2CUSP2ALDH1A1HPGD | |
| SCHEMBL1395855 | 0.81 | HTR2A (0.55) | HTR2AHTR2CUSP2ALDH1A1HPGD | |
| SCHEMBL17553681 | 0.81 | HTR2A (0.57) | HTR2AHTR2CUSP2ALDH1A1HPGD | |
| SCHEMBL15348868 | 0.81 | HTR2A (0.57) | HTR2AHTR2CUSP2ALDH1A1HPGD | |
| SCHEMBL20365440 | 0.80 | HTR2A (0.54) | HTR2AHTR2CUSP2ALDH1A1HPGD | |
| SCHEMBL15024522 | 0.80 | HTR2A (0.69) | HTR2AHTR2CUSP2ALDH1A1HPGD | |
| SCHEMBL26370481 | 0.78 | HPGD (0.46) | HTR2AHTR2CUSP2ALDH1A1HPGD | |
| SCHEMBL12450045 | 0.78 | HTR2A (0.74) | HTR2AHTR2CUSP2ALDH1A1HPGD | |
| SCHEMBL23691134 | 0.78 | HTR2A (0.55) | HTR2AHTR2CUSP2ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018119441-A9 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2019-10-10 | — | — | WO | disclosed |
| WO-2018119441-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | Arvinas, Inc. (US) | 2018-06-28 | — | — | WO | disclosed |
| WO-2018091885-A1 | HYDROXYLATION OF BRANCHED ALIPHATIC OR AROMATIC SUBSTRATES EMPLOYING THE AMYCOLATOPSIS LURIDA CYTOCHROME P450 | HYPHA DISCOVERY LIMITED (GB) | 2018-05-24 | — | — | WO | disclosed |
| WO-2016029839-A1 | (SUBSTITUTED PHENYL) (SUBSTITUTED PYRIMIDINE) AMINO DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICATION USE | 四川海思科制药有限公司 | 2016-03-03 | — | — | WO | disclosed |
| US-20140357599-A1 | NOVEL UREA AND THIOUREA DERIVATIVES | ONXEO DK, BRANCH OF ONXEO S.A., FRANCE (DK) | 2014-12-04 | — | — | US | disclosed |
| US-20140357599-A1 | NOVEL UREA AND THIOUREA DERIVATIVES | ONXEO DK, BRANCH OF ONXEO S.A., FRANCE (DK) | 2014-12-04 | — | — | US | disclosed |
| US-8871747-B2 | Urea and thiourea derivatives | TOPOTARGET A/S (DK) | 2014-10-28 | — | — | US | disclosed |
| US-8871747-B2 | Urea and thiourea derivatives | TOPOTARGET A/S (DK) | 2014-10-28 | — | — | US | disclosed |
| US-20120010172-A1 | NOVEL UREA AND THIOUREA DERIVATIVES | MCDERMOTT WILL & EMERY LLP (DC) | 2012-01-12 | — | — | US | disclosed |
| US-20120010172-A1 | NOVEL UREA AND THIOUREA DERIVATIVES | MCDERMOTT WILL & EMERY LLP (DC) | 2012-01-12 | — | — | US | disclosed |
| WO-2010023307-A1 | NOVEL UREA AND THIOUREA DERIVATIVES | TOPOTARGET A/S (DK) | 2010-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010172-A1 | NOVEL UREA AND THIOUREA DERIVATIVES | TST, NAMPT, NNMT | HTR2A 4341/4885HTR2C 4534/4885USP2 2139/4885 |
| US-20140357599-A1 | NOVEL UREA AND THIOUREA DERIVATIVES | TST, NAMPT, NNMT | HTR2A 4341/4885HTR2C 4534/4885USP2 2139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.